This suggests that combination therapies pairing KRAS G12C inhibitors with other approaches, such as chemoradiotherapy and immunotherapies, may help improve outcomes in gastric cancer, but high-quality clinical trials are further required. This evidence concerns the gene KRAS and gastric cancer.